






BMJ Open Association of cardiometabolic risk factors with hospitalisation or death due to COVID-19: population-based cohort study in Sweden (SCAPIS)

Per Tornhammar,¹ Tomas Jernberg,² Göran Bergström,^{3,4} Anders Blomberg,⁵ Gunnar Engström,⁶ Jan Engvall,^{7,8} Tove Fall ,⁹ Magnus Gisslén,^{10,11} Christer Janson ,¹² Lars Lind,¹³ C Magnus Sköld,^{14,15} Johan Sundström,^{13,16} Stefan Söderberg ,⁵ Suneela Zaigham,⁶ Carl Johan Östgren,⁸ Daniel Peter Andersson ,¹⁷ Peter Ueda ¹⁸

To cite: Tornhammar P, Jernberg T, Bergström G, *et al.* Association of cardiometabolic risk factors with hospitalisation or death due to COVID-19: population-based cohort study in Sweden (SCAPIS). *BMJ Open* 2021;**11**:e051359. doi:10.1136/bmjopen-2021-051359

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-051359>).

DPA and PU are joint senior authors.

Received 18 March 2021
Accepted 18 August 2021



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Peter Ueda; peter.ueda@ki.se

ABSTRACT

Objective To assess the association of cardiometabolic risk factors with hospitalisation or death due to COVID-19 in the general population.

Design, setting and participants Swedish population-based cohort including 29 955 participants.

Exposures Cardiometabolic risk factors assessed between 2014 and 2018.

Main outcome measures Hospitalisation or death due to COVID-19, as registered in nationwide registers from 31 January 2020 through 12 September 2020. Associations of cardiometabolic risk factors with the outcome were assessed using logistic regression adjusted for age, sex, birthplace and education.

Results Mean (SD) age was 61.2 (4.5) and 51.5% were women. 69 participants experienced hospitalisation or death due to COVID-19. Examples of statistically significant associations between baseline factors and subsequent hospitalisation or death due to COVID-19 included overweight (adjusted OR (aOR) vs normal weight 2.73 (95% CI 1.25 to 5.94)), obesity (aOR vs normal weight 4.09 (95% CI 1.82 to 9.18)), pre-diabetes (aOR vs normoglycaemia 2.56 (95% CI 1.44 to 4.55)), diabetes (aOR vs normoglycaemia 3.96 (95% CI 2.13 to 7.36)), sedentary time (aOR per hour/day increase 1.10 (95% CI 1.02 to 1.17)), grade 2 hypertension (aOR vs normotension 2.44 (95% CI 1.10 to 5.44)) and high density lipoprotein cholesterol (aOR per mmol/L increase 0.33 (95% CI 0.17 to 0.65)). Statistically significant associations were not observed for grade 1 hypertension (aOR vs normotension 1.03 (95% CI 0.55 to 1.96)), current smoking (aOR 0.56 (95% CI 0.24 to 1.30)), total cholesterol (aOR per mmol/L increase 0.90 (95% CI 0.71 to 1.13)), low density lipoprotein cholesterol (aOR per mmol/L increase 0.90 (95% CI 0.69 to 1.15)) and coronary artery calcium score (aOR per 10 units increase 1.00 (95% CI 0.99 to 1.01)).

Conclusions In a large population-based sample from the general population, several cardiometabolic risk factors were associated with hospitalisation or death due to COVID-19.

Strengths and limitations of this study

- This study used data on cardiometabolic risk factors measured between 2014 and 2018 in a population-based cohort of almost 30 000 participants and assessed their association with hospitalisation or death due to COVID-19 during the first wave of the pandemic.
- Few previous studies have used population-based samples from the general population to assess the relationship between cardiometabolic risk factors and outcomes in COVID-19.
- As we could not capture all cases of COVID-19 which did not lead to hospitalisation or death, we could not assess to what extent the observed associations may reflect the relationship with exposure to SARS-CoV-2 as compared with the risk of hospitalisation or death due to COVID-19 among those who have been exposed to the virus.

Identification of individuals at risk of worse outcomes in COVID-19 may inform risk management decisions to mitigate exposure and to prioritise vaccination. Several studies have shown that cardiometabolic risk factors are associated with a higher risk of adverse outcomes in COVID-19. While many of these studies have been performed in selected populations such as patients hospitalised with COVID-19^{1 2} or patients with certain diagnoses,^{3 4} fewer studies have been based on data from the general population.^{5–8}

The Swedish CARDioPulmonary bioImage Study (SCAPIS)⁹ is a population-based cohort of approximately 30 000 men and women who were extensively characterised with respect to cardiometabolic risk factors and function at the age of 50–64 years during the years preceding the COVID-19 outbreak

(2014 through 2018). We used data from SCAPIS to assess the association of cardiometabolic risk factors with risk of hospitalisation or death due to COVID-19 during the first wave of the pandemic.

METHODS

Data sources

The SCAPIS cohort, described in detail elsewhere,⁹ is a population-based cohort conducted at six Swedish university hospitals in Gothenburg, Linköping, Malmö/Lund, Stockholm, Umeå and Uppsala, with each site recruiting participants from corresponding municipality areas. From 2014 through 2018, over 30 000 participants aged 50–64 years underwent examinations of cardiopulmonary risk factors and provided information regarding lifestyle factors and socioeconomic conditions. Using the personal identity number, we linked SCAPIS data to nationwide administrative and health registers. From the National Patient Register, which comprises physician-assigned diagnoses based on the International Classification of Diseases, 10th Revision, Swedish Edition (ICD-10-SE) for all hospital admissions in Sweden, we obtained information about hospitalisation for COVID-19. From the Cause of Death register, we obtained data about vital status, and date and cause of death. From SmiNet,¹⁰ a reporting system for infectious diseases administered by the Public Health Agency, we obtained information about laboratory-confirmed cases of COVID-19, including those not leading to hospitalisation or death.

Outcomes, exposures, and study period

The main outcome was a composite of hospitalisation due to COVID-19 and death due to COVID-19. Hospitalisation for COVID-19 was defined as hospital admission with laboratory-confirmed COVID-19 as the primary diagnosis (ICD-10-SE code U07.1 (COVID-19, virus identified)).¹¹ Death due to COVID-19 was defined as death where U07.1 was specified as the underlying cause of death. Follow-up was from 31 January 2020 (the first laboratory-confirmed case of COVID-19 in Sweden) through 12 September 2020.

We included variables in the SCAPIS data set (described in detail in online supplemental table 1) that we hypothesised could be associated with hospitalisation or death due to COVID-19: these included sociodemographic variables (age, sex, place of birth and education) and cardiometabolic risk factors: diabetes status (normoglycaemia, pre-diabetes, diabetes); weight status (normal (body mass index (BMI) <25 kg/m²), overweight (BMI ≥25 kg/m² to <30 kg/m²), obesity (BMI ≥30 kg/m²)); current smoking, waist-hip ratio, blood pressure status (normotension, grade 1 hypertension, grade 2 hypertension); systolic and diastolic blood pressure; coronary artery calcium score; total cholesterol; low density lipoprotein (LDL) cholesterol; high density lipoprotein (HDL) cholesterol; glycated haemoglobin and creatinine. Few (≤2%) participants had established cardiovascular

disease, including coronary heart disease, stroke and heart failure; therefore, we did not assess these variables.

Study population

We included all 30 154 participants in SCAPIS. We excluded 2 participants who had missing data on vital status and 197 participants who died before 31 January 2020. The study population included 29 955 participants.

Statistical analysis

Analyses were performed in Stata V.16.0. We described study participants with respect to the selected variables, separately among those who did not experience hospitalisation or death due to COVID-19 and among those who did and assessed differences between the groups using the χ^2 test for categorical variables and the t-test for continuous variables. For each investigated variable separately, we used logistic regression to assess its association with hospitalisation or death due to COVID-19, adjusting for sociodemographic variables including age (continuous variable), sex, place of birth (outside of Sweden vs Sweden) and education (high school or less, vocational, university).¹² Analyses were performed among those with complete data for all variables included in the model. The proportion of missing data for the analysed variables are shown in online supplemental table 1 and ranged between 0% and 5% (0%–8% in the main analyses using those with complete data on the variables assessed and adjusted for); the exception was time spent sedentary per day for which 34.9% of the participants had missing data. In post-hoc sensitivity analyses, we performed the main analyses with more than 5% missing data (those assessing waist-hip ratio, time spent sedentary per day and coronary artery calcium score) using multiple imputation (10 imputed data sets) created with chained equations.

The relationship between the investigated variables and hospitalisation or death due to COVID-19 may not only represent the risk of worse COVID-19 outcomes in individuals exposed to SARS-CoV-2 but also the risk of exposure to SARS-CoV-2. We therefore performed an additional analysis restricted to the subgroup of participants (n=299) with a laboratory-confirmed COVID-19 diagnosis as recorded in SmiNet, the National Patient Register or the Cause of Death Register (ie, participants with a laboratory-confirmed of COVID-19, including both those who did and did not experience hospitalisation or death due to COVID-19). In this subgroup, we used logistic regression to assess the association of each of the cardiometabolic risk factors (separately) with hospitalisation or death due to COVID-19. ORs whose 95% CI did not overlap 1 were considered as statistically significant.

Patient involvement

No patients were involved in setting the research question, nor in the design, conduct or interpretation of the study. The study findings are planned to be disseminated through the SCAPIS website.

Table 1 Characteristics of SCAPIS participants by experience of hospitalisation or death due to COVID-19 between 31 January and 12 September 2020

	Hospitalisation or death due to COVID-19		P value
	No (n=29886)	Yes (n=69)	
Age, mean (SD)	61.2 (4.5)	61.9 (4.8)	0.226
Men	14 483 (48.5)	52 (75.4)	<0.001
Born outside of Sweden	4725 (16.3)	22 (32.4)	<0.001
Education			
High school or less	2700 (9.3)	12 (17.9)	
Vocational	13 218 (45.5)	31 (46.3)	
University	13 125 (45.2)	24 (35.8)	0.036
Weight status			
Normal weight	10 738 (35.9)	8 (11.6)	
Overweight	12 814 (42.9)	36 (52.2)	
Obesity	6332 (21.2)	25 (36.2)	<0.001
Body mass index in kg/m ² , mean (SD)	27.0 (4.5)	30.0 (5.3)	<0.001
Diabetes status			
Normoglycaemia	22 774 (76.6)	32 (46.4)	
Pre-diabetes	4727 (15.9)	20 (29.0)	
Diabetes	2240 (7.5)	17 (24.6)	<0.001
Waist-hip ratio, mean (SD)	0.92 (0.09)	0.98 (0.09)	<0.001
Current smoking	3785 (13.1)	6 (9)	0.317
Sedentary time per day in hours, mean (SD)	6.9 (3.5)	8.3 (4.5)	0.009
Blood pressure measurement			
Normotensive	23 285 (78.3)	50 (72.5)	
Grade 1 hypertension	5129 (17.3)	12 (17.4)	
Grade 2 hypertension	1319 (4.4)	7 (10.1)	0.069
Systolic blood pressure, mean (SD)	125.9 (17.0)	133.5 (19.5)	<0.001
Diastolic blood pressure, mean (SD)	77.5 (10.5)	81.0 (12.4)	0.006
Triglycerides in mmol/L, mean (SD)	1.2 (0.8)	1.6 (1.1)	<0.001
HDL in mmol/L, mean (SD)	1.6 (0.5)	1.3 (0.4)	<0.001
Total cholesterol in mmol/L, mean (SD)	5.5 (1.1)	5.3 (1.0)	0.068
LDL cholesterol in mmol/L, mean (SD)	3.4 (1.0)	3.3 (0.9)	0.360
Glycated haemoglobin in mmol/mol, mean (SD)	36.6 (6.4)	39.7 (9.3)	<0.001
Creatinine in µmol/L, mean (SD)	77.7 (16.4)	86.2 (37.9)	<0.001
Coronary artery calcium score, mean (SD)	61.6 (229.5)	90.2 (199.6)	0.053*

Numbers are shown in N (%) unless otherwise indicated.

*Because 17 016 of the participants had a score of 0, the p value calculated using the χ^2 with five categories: 0 and quartiles of score among participants with a score of >0.

HDL, high density lipoprotein; LDL, low density lipoprotein; SCAPIS, Swedish CArdioPulmonary bioImage Study.

RESULTS

Characteristics of the 29 955 study participants are shown in [table 1](#). Fourteen thousand five hundred thirty-five (48.5%) were men. Mean (SD) age was 61.2 (4.5) years. Sixty-nine (0.2%) of the participants were hospitalised or died due to COVID-19. Those who experienced (n=69) versus did not experience (n=29 886) hospitalisation or death due to COVID-19 were slightly older (61.9 years vs 61.2 years) and more likely to be men (75.4% vs 48.5%),

born outside of Sweden (32.4% vs 16.3%) and to have education of high school or less (17.9% vs 9.3%).

The results of the logistic regression assessing the association between each of the selected cardiometabolic risk factors and hospitalisation or death due to COVID-19 (adjusted for age, sex, place of birth and education) are shown in [table 2](#). Significant associations were observed for overweight and obesity, higher body mass index, pre-diabetes, diabetes, higher waist-hip ratio, more time

Table 2 OR (95% CI)*, adjusted for age, sex, place of birth and education, for the association of selected variables with hospitalisation or death due to COVID-19 in the main and additional analyses

	Main analysis (n=29 955)	Additional analysis restricted to those with laboratory-confirmed COVID-19 diagnosis (n=299)
Age per year	1.03 (0.97 to 1.08)	1.11 (1.04 to 1.20)
Men	3.39 (1.93 to 5.95)	6.62 (3.45 to 12.71)
Born outside of Sweden	2.40 (1.43 to 4.03)	1.59 (0.80 to 3.18)
Education†		
High school or less	1.00 (ref)	1.00 (ref)
Vocational	0.58 (0.30 to 1.14)	0.41 (0.16 to 1.09)
University	0.49 (0.24 to 0.99)	0.26 (0.10 to 0.70)
Weight status		
Normal weight	1.00 (ref)	1.00 (ref)
Overweight	2.73 (1.25 to 5.94)	3.41 (1.41 to 8.27)
Obesity	4.09 (1.82 to 9.18)	4.86 (1.86 to 12.71)
Body mass index per 5 kg/m ² increase	1.77 (1.43 to 2.19)	2.05 (1.44 to 2.92)
Diabetes status		
Normoglycaemia	1.00 (ref)	1.00 (ref)
Pre-diabetes	2.56 (1.44 to 4.55)	3.72 (1.68 to 8.28)
Diabetes	3.96 (2.13 to 7.36)	5.12 (1.95 to 13.42)
Waist-hip ratio per SD increase	1.55 (1.20 to 2.00)	1.92 (1.20 to 3.06)
Sedentary time per day per hour increase	1.10 (1.02 to 1.17)	1.13 (1.02 to 1.26)
Blood pressure measurement		
Normotensive	1.00 (ref)	1.00 (ref)
Grade 1 hypertension	1.03 (0.55 to 1.96)	0.95 (0.41 to 2.17)
Grade 2 hypertension	2.44 (1.10 to 5.44)	4.18 (1.07 to 16.32)
Systolic blood pressure per 10 mm Hg increase	1.22 (1.07 to 1.40)	1.21 (1.01 to 1.44)
Diastolic blood pressure per 10 mm Hg increase	1.31 (1.05 to 1.64)	1.30 (0.97 to 1.73)
Current smoking	0.56 (0.24 to 1.30)	0.87 (0.28 to 2.71)
Triglycerides per mmol/L increase	1.10 (1.00 to 1.21)	1.34 (0.98 to 1.85)
HDL per mmol/L increase	0.33 (0.17 to 0.65)	0.26 (0.10 to 0.66)
Total cholesterol per mmol/L increase	0.90 (0.71 to 1.13)	0.80 (0.59 to 1.10)
LDL cholesterol per mmol/L increase	0.90 (0.69 to 1.15)	0.83 (0.59 to 1.17)
Glycated haemoglobin per mmol/mol increase	1.03 (1.01 to 1.05)	1.04 (1.00 to 1.09)
Creatinine per 10 µmol/L increase	1.05 (1.00 to 1.10)	1.04 (0.88 to 1.23)
Coronary artery calcium score per 10 units increase	1.00 (0.99 to 1.01)	1.00 (0.98 to 1.02)

*Reference group for binary variables (yes/no) is 'no'.

†Adjusted for sex and place of birth.

HDL, high density lipoprotein; LDL, low density lipoprotein.

spent sedentary per day, grade 2 hypertension, as well as higher systolic blood pressure, diastolic blood pressure, triglycerides and glycated haemoglobin and lower HDL cholesterol. Significant associations were not observed for grade 1 hypertension, current smoking, total cholesterol, LDL cholesterol, creatinine and coronary artery calcium

score. In the post-hoc sensitivity analyses using multiple imputation for logistic regression models with over 5% missing data, the results were similar to those in the main analyses: waist-hip ratio (OR per SD increase 1.54 (95% CI 1.20 to 1.98), time spent sedentary per day (OR per hour increase 1.09 (95% CI 1.01 to 1.18) and coronary

artery calcium score (OR per 10 units increase 1.00 (95% CI 0.99 to 1.01))

Population characteristics for the additional analysis including the 299 participants with laboratory confirmed COVID-19 are shown in online supplemental table 2. Compared with the total study population, those with a laboratory-confirmed diagnosis of COVID-19 were less likely to be men and to be current smokers and more likely to be born outside of Sweden. The results of the logistic regression analyses are shown in table 2. The findings were largely similar to those of the main analysis.

DISCUSSION

We assessed the association of cardiometabolic risk factors with risk of hospitalisation or death due to COVID-19 during the first wave of the pandemic in a Swedish population-based cohort with nearly 30 000 participants aged 52–72 years in 2020.

In analyses adjusted for age, sex, place of birth and education, we found that several cardiometabolic risk factors were associated with an increased risk of hospitalisation or death due to COVID-19. Significant associations were found for metabolic risk factors, including overweight, obesity, pre-diabetes, diabetes and higher waist-hip ratio and glycated haemoglobin; findings that are in line with previous studies on these or related risk factors.^{7 8 13} While significant associations were observed for grade 2 hypertension and for systolic and diastolic blood pressure when analysed as continuous variables, grade 1 hypertension was not associated with an increased risk. Moreover, while lower HDL cholesterol and higher triglycerides were associated with hospitalisation or death due to COVID-19, such associations were not observed for LDL cholesterol or total cholesterol. Associations with hospitalisation or death due to COVID-19 were also not observed for current smoking and a higher coronary artery calcium score. Previous studies on the association of smoking, hypertension, lipid levels and coronary artery calcium score with COVID-19 outcomes have yielded mixed findings.^{8 14–18}

Strengths of our study include the use of a large sample from the general population who had undergone assessment of cardiometabolic risk factors in the years preceding the pandemic. Our study has limitations. Although the SCAPIS cohort includes detailed data on cardiometabolic risk factors from a large number of participants, the limited number of COVID-19 cases leading to hospitalisation or death resulted in wide CIs for some of the analyses. Moreover, during the first months of the pandemic, laboratory testing for COVID-19 was not widely performed and predominantly focused on healthcare professionals and hospitalised patients.¹⁹ As such, although the findings of our analyses restricted to those with a laboratory-confirmed COVID-19 diagnosis were similar to those of our main analyses (although the analyses were based on a small sample of 299 participants), we could not assess to what extent the observed associations may reflect the

relationship with exposure to SARS-CoV-2 as compared with the risk of hospitalisation or death due to COVID-19 among those who have been exposed to the virus. Updated analyses may be performed as data on broader testing for COVID-19 and more cases of hospitalisation or death due to COVID-19 become available. Finally, the study included individuals in a limited age range.

CONCLUSION

In this study, large population-based cohort from the general population, several cardiometabolic risk factors were associated with hospitalisation or death due to COVID-19.

Author affiliations

¹Functional Area of Emergency Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden

²Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden

³Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

⁴Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁵Department of Public Health and Clinical Medicine, Section of Medicine, Umeå University, Umeå, Sweden

⁶Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden

⁷CMIV, Centre of Medical Image Science and Visualization, Linköping University, Linköping, Sweden

⁸Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

⁹Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

¹⁰Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

¹¹Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

¹²Department of Medical Sciences, Respiratory-, Allergy- and Sleep Research, Uppsala University, Uppsala, Sweden

¹³Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden

¹⁴Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Stockholm, Sweden

¹⁵Department of Respiratory Medicine and Allergy, Karolinska University Hospital Solna, Stockholm, Sweden

¹⁶The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia

¹⁷Department of Medicine Huddinge H7, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

¹⁸Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Twitter Tove Fall @falltove

Contributors PU had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. PT, TJ, TF, CJ, MS, DPA and PU developed the research design. PT, TJ, GB, AB, GE, JE, TF, MG, CJ, LL, MS, JS, SS, SZ, CJO, DPA and PU contributed to the acquisition, analysis or interpretation of data. DPA and PU drafted first draft of the manuscript. PT, TJ, GB, AB, GE, JE, TF, MG, CJ, LL, MS, JS, SS, SZ, CJO, DPA and PU critically reviewed and revised the manuscript for important intellectual content and approved the manuscript. PU performed the statistical analysis. TJ and PU obtained funding.

Funding The study was supported by a grant from the Swedish Heart-Lung Foundation (grant number 20200491). PU was supported by grants from the Swedish Heart-Lung Foundation and the Swedish Society for Medical Research. DPPA was supported by grants from CIMED (grant number 20180855). The main funding body of The Swedish CardioPulmonary biolmage Study (SCAPIS) is the Swedish Heart-Lung Foundation. The study is also funded by the Knut and Alice

Wallenberg Foundation, the Swedish Research Council and VINNOVA (Sweden's Innovation agency), the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institute and Stockholm county council, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, Uppsala University and University Hospital.

Disclaimer The funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript and decision to submit the manuscript for publication.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the Ethical Review Board in Umeå, Sweden (reference numbers: 2010-228-31M and 2020-02668).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Tove Fall <http://orcid.org/0000-0003-2071-5866>

Christer Janson <http://orcid.org/0000-0001-5093-6980>

Stefan Söderberg <http://orcid.org/0000-0001-9225-1306>

Daniel Peter Andersson <http://orcid.org/0000-0003-4655-4837>

Peter Ueda <http://orcid.org/0000-0002-3275-8743>

REFERENCES

- 1 Wu C, Chen X, Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.*
- 2 Docherty AB, Harrison EM, Green CA. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC who clinical characterisation protocol: prospective observational cohort study. *BMJ* 1985;2020.
- 3 McGurnaghan SJ, Weir A, Bishop J. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. *Lancet Diabetes Endocrinol.*
- 4 Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol* 2020;8:813–22.
- 5 Reilev M, Kristensen KB, Pottgård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. *Int J Epidemiol* 2020;49:1468–81.
- 6 Petrilli CM, Jones SA, Yang J. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 1966;2020.
- 7 Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* 2020;371:m3731.
- 8 Hamer M, Gale CR, Kivimäki M, et al. Overweight, obesity, and risk of hospitalization for COVID-19: a community-based cohort study of adults in the United Kingdom. *Proc Natl Acad Sci U S A* 2020;117:21011–3.
- 9 Bergström G, Berglund G, Blomberg A, et al. The Swedish cardiopulmonary biolmage study: objectives and design. *J Intern Med* 2015;278:645–59.
- 10 Rolfhamre P, Janson A, Arneborn M, et al. SmiNet-2: description of an Internet-based surveillance system for communicable diseases in Sweden. *Euro Surveill* 2006;11:15–16.
- 11 Ludvigsson JF. The first eight months of Sweden's COVID-19 strategy and the key actions and actors that were involved. *Acta Paediatr* 2020;109:2459–71.
- 12 Drefahl S, Wallace M, Mussino E, et al. A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. *Nat Commun* 2020;11:5097.
- 13 Xie J, Zu Y, Alkhatib A, et al. Metabolic syndrome and COVID-19 mortality among adult black patients in New Orleans. *Diabetes Care* 2021;44:188–93.
- 14 Garg H, Khanna P. Covid and cholesterol (C&C): Something to worry about or much ado about nothing? *Trends Anaesth Crit Care.*
- 15 Hopkinson NS, Rossi N, El-Sayed Moustafa J, et al. Current smoking and COVID-19 risk: results from a population symptom APP in over 2.4 million people. *Thorax* 2021;76:714–22.
- 16 Smoking WT. and COVID-19 - A review of studies suggesting a protective effect of smoking against COVID-19. *EU Sci. Hub.*
- 17 Dillinger JG, Benmessaoud FA, Pezel T, et al. Coronary artery calcification and complications in patients with COVID-19. *JACC Cardiovasc Imaging* 2020;13:2468–70.
- 18 Clark CE, McDonagh STJ, McManus RJ. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish hypertension society. *J Hum Hypertens* 2021;1–4.
- 19 Ludvigsson JF. The first eight months of Sweden's COVID-19 strategy and the key actions and actors that were involved. *Acta Paediatr* 2020;15582.